DDX42 and hepatocellular carcinoma: In contrast, overexpression of DDX42 in hepatocellular carcinoma activates the PI3K/AKT signaling pathway, enhancing proliferation, radioresistance, and sorafenib resistance, suggesting context-dependent oncogenic activity [71].